15.1 Hospital-Acquired & Ventilator-Associated Pneumonia

Diagnostic Definitions and Nosocomial Pathophysiology

Pneumonia acquired in the healthcare setting represents one of the most common and morbid complications encountered in the intensive care unit. The 2016 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines established standardized definitions that delineate nosocomial pulmonary infections based on artificial airway status and timing:

1. Hospital-Acquired Pneumonia (HAP): An acute lower respiratory tract infection occurring $\ge 48\text{ hours}$ after hospital admission that was neither present nor incubating at the time of initial hospitalization, developing in a non-intubated patient.
2. Ventilator-Associated Pneumonia (VAP): An acute lower respiratory tract infection developing $> 48\text{ hours}$ following invasive endotracheal intubation and mechanical ventilation.

Pathophysiologic Cascade of VAP

The pathogenetic sequence of VAP is primarily driven by the physical and immunological disruptions imposed by the endotracheal tube (ETT):

• Upper Airway Bypass: The ETT prevents normal glottic closure, blunts the cough reflex, and disables mucociliary transport.
• Subglottic Secretion Pooling: Contaminated oral, pharyngeal, and refluxed gastric secretions pool in the subglottic dead space directly above the inflated ETT cuff.
• Microaspiration: Longitudinal folds inherent in polyvinyl chloride (PVC) cuffs permit intermittent microaspiration of contaminated subglottic fluid into the lower respiratory tract, particularly during patient repositioning, ventilator cycling, and coughing.
• Biofilm Formation: Within hours of intubation, a polymicrobial polysaccharide-protein biofilm lines the inner lumen of the ETT. Shearing forces from ventilator gas flow and endotracheal suction catheters dislodge bacterial aggregates directly into distal terminal bronchioles and alveoli.
• Host Defense Failure: Critically ill hosts exhibit impaired alveolar macrophage phagocytosis, alveolar epithelial injury, and surfactant dysfunction, culminating in purulent alveolar exudation, severe ventilation-perfusion ($V_A/Q$) mismatch, and systemic inflammatory cascade activation.

---

Diagnostic Sampling: Non-Invasive vs. Invasive Strategies

Establishing an accurate microbiological diagnosis in suspected VAP is critical for directing pathogen-specific therapy and facilitating early antimicrobial de-escalation. The clinical diagnosis of VAP—classically based on a new or progressive radiographic infiltrate paired with systemic signs of infection (fever or hypothermia, leukocytosis or leukopenia, and purulent sputum)—demonstrates poor diagnostic accuracy when used in isolation, frequently conflating pneumonia with atelectasis, ARDS, pulmonary infarction, or alveolar hemorrhage.

Quantitative Microbiological Sampling Thresholds

To distinguish bacterial colonization of the upper airway from true parenchymal alveolar infection, clinicians rely on quantitative culture thresholds. Each sampling modality carries a specific diagnostic colony-forming unit (CFU) cutoff:

---

ATS/IDSA Empiric Antimicrobial Therapy Guidelines

Empiric antimicrobial regimens for VAP and severe HAP must be initiated promptly upon clinical suspicion, following the collection of lower respiratory tract and blood cultures. Regimen selection is governed by three determinants: risk factors for multidrug-resistant (MDR) pathogens, local ICU antibiogram data, and patient mortality risk.

Core Risk Factors for Multidrug-Resistant (MDR) Pathogens in VAP

The presence of any of the following validated risk factors significantly elevates the likelihood of infection caused by methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, extended-spectrum $\beta$-lactamase (ESBL)-producing Enterobacteriaceae, or carbapenem-resistant organisms:

1. Prior intravenous antibiotic therapy within the preceding 90 days.
2. Septic shock at the time of VAP onset.
3. Acute Respiratory Distress Syndrome (ARDS) preceding the development of VAP.
4. Hospitalization duration $\ge 5\text{ days}$ prior to VAP onset.
5. Acute renal replacement therapy (RRT) required prior to VAP onset.

Indications for Empiric MRSA Coverage

Empiric MRSA coverage is indicated if any of the following criteria are met:

• Presence of a risk factor for antimicrobial resistance (prior IV antibiotics within 90 days).
• Patient is managed in an intensive care unit where $> 10\text{--}20\%$ of S. aureus isolates are methicillin-resistant, or where the local MRSA prevalence is unknown.
• Patient is at high risk of mortality (septic shock or need for ventilatory support secondary to HAP).

Antimicrobial Selection for MRSA:

• Vancomycin: Dosed $15\text{--}20\text{ mg/kg}$ IV every $8\text{--}12\text{ hours}$ (adjusted for renal clearance), targeting an area under the curve to minimum inhibitory concentration ratio ($\text{AUC}_{24}/\text{MIC}$) of $400\text{--}600\text{ mg}\cdot\text{h/L}$, preferably by Bayesian software; the 2020 ASHP/IDSA consensus no longer recommends trough-only targets of 15-20 mcg/mL because they increase nephrotoxicity. Requires careful therapeutic drug monitoring; carries risk of acute tubular necrosis, especially when combined with piperacillin-tazobactam.
• Linezolid: Dosed $600\text{ mg}$ IV every $12\text{ hours}$. Linezolid achieves higher penetration into pulmonary epithelial lining fluid (ELF) compared to vancomycin and causes no nephrotoxicity. Adverse effects include reversible myelosuppression (thrombocytopenia), peripheral/optic neuropathy, and risk of serotonin syndrome when co-administered with serotonergic agents.

Indications for Double Antipseudomonal Coverage

Empiric double coverage targeting Pseudomonas aeruginosa and other resistant Gram-negative bacilli requires administering two antipseudomonal agents from distinct pharmacological classes. Indications include:

• Any validated MDR risk factor (prior IV antibiotics within 90 days, septic shock, ARDS preceding VAP, $\ge 5$ days hospital stay, or acute RRT).
• Hospital units where $> 10\%$ of Gram-negative isolates are resistant to candidate monotherapy beta-lactams.
• High risk of mortality (ventilator dependence from HAP or septic shock).

                    SUSPECTED VAP / SEVERE HAP
                                │
          ┌─────────────────────┴─────────────────────┐
          ▼                                           ▼
  MDR Risk Factors Present?                  No MDR Risk Factors & 
  - Prior IV antibiotics <90d                - Local MRSA <10-20%
  - Septic shock                             - Local GNB resistance <10%
  - ARDS preceding VAP                       - No shock or high mortality risk
  - Hospital stay >=5 days                            │
  - Acute RRT prior to VAP                            ▼
          │                               Antipseudomonal Monotherapy:
          │ YES                           - Cefepime OR
          ▼                               - Piperacillin-tazobactam OR
  TRIPLE DRUG REGIMEN:                    - Meropenem OR
  1. MRSA Agent (Vancomycin / Linezolid)  - Levofloxacin
  2. Antipseudomonal Beta-Lactam
  3. Second Antipseudomonal Agent
     (Aminoglycoside OR Fluoroquinolone)

Empiric Regimen Architecture

Duration of Therapy and De-escalation

• Standard 7-Day Duration: The 2016 ATS/IDSA guidelines recommend a standard 7-day course of antimicrobial therapy for patients with VAP or HAP who demonstrate clinical improvement. Multiple randomized trials established that a 7-day course yields equivalent clinical cure rates, identical 28-day mortality, and significantly fewer recurrent infections caused by resistant pathogens compared to 10- to 14-day courses, even for non-fermenting Gram-negative bacilli such as Pseudomonas aeruginosa.
• Microbiological De-escalation: Empiric regimens should be narrowed within 48 to 72 hours based on definitive culture and susceptibility profiles. When negative quantitative cultures ($< 10^4\text{ CFU/mL}$ on BAL) accompany clinical improvement or an alternative diagnosis, antibiotics can be safely discontinued.
• Procalcitonin (PCT) Kinetics: Serial serum procalcitonin levels, evaluated alongside clinical trajectory, guide early antimicrobial discontinuation (e.g., discontinuation when PCT drops by $\ge 80\%$ from peak or falls $< 0.25\text{ mcg/L}$). Procalcitonin should not be used to withhold initial empiric therapy in suspected sepsis.

---

Evidence-Based VAP Prevention Bundles

Implementing structured, multidisciplinary care bundles substantially curtails the incidence of VAP, reduces ICU length of stay, and minimizes healthcare costs. The Institute for Healthcare Improvement (IHI) and the Society for Healthcare Epidemiology of America (SHEA) endorse the following core bundle interventions:

VAP Prevention Bundle Checklist

1. Head of Bed (HOB) Elevation to $30^\circ\text{--}45^\circ$:
   • Physiologic Rationale: Prevents passive gastroesophageal reflux and gravity-dependent retrograde flow of gastric contents into the hypopharynx, significantly decreasing microaspiration.
   • Contraindications: Severe spinal trauma prior to clearance, unstable pelvic fractures, active prone positioning for ARDS, or profound hemodynamic shock requiring flat supine positioning.
2. Daily Sedative Interruption & Spontaneous Breathing Trials (SAT / SBT):
   • Physiologic Rationale: Daily paired "wake up and breathe" protocols (Spontaneous Awakening Trials [SAT] paired with Spontaneous Breathing Trials [SBT]) reduce cumulative sedative accumulation, shorten duration of invasive mechanical ventilation, and accelerate successful extubation, thereby eliminating ETT dwell time.
3. Subglottic Secretion Drainage (CASS):
   • Physiologic Rationale: Specialized endotracheal tubes equipped with an integrated dorsal evacuation lumen opening immediately above the cuff allow continuous or intermittent aspiration of contaminated secretions pooling in the subglottic space. Meta-analyses demonstrate a $40\text{--}50\%$ reduction in VAP rates, particularly in patients anticipated to require ventilation for $> 48\text{--}72\text{ hours}$.
4. Endotracheal Tube Cuff Pressure Management ($20\text{--}30\text{ cmH}_2\text{O}$):
   • Physiologic Rationale: Cuff pressures must be measured continuously or intermittently with a calibrated manometer. Pressures $< 20\text{ cmH}_2\text{O}$ allow microaspiration of pooled secretions around the cuff folds; pressures $> 30\text{ cmH}_2\text{O}$ exceed tracheal mucosal capillary perfusion pressure ($25\text{--}30\text{ mmHg}$), inducing mucosal ischemia, ulceration, chondritis, tracheomalacia, and subsequent tracheal stenosis.
5. Stress Ulcer Prophylaxis (SUP) Stewardship:
   • Physiologic Concern: Acid suppression raises gastric pH and permits gastric bacterial overgrowth, which has long been suspected of increasing VAP and C. difficile infection.
   • Current Evidence: In REVISE (NEJM 2024; 4,821 ventilated adults), pantoprazole 40 mg daily reduced clinically important upper GI bleeding (1.0% vs. 3.5%; HR 0.30) without changing 90-day mortality (29.1% vs. 30.9%) or increasing VAP or C. difficile infection. Earlier, SUP-ICU (NEJM 2018) found no mortality effect.
   • Practical Rule: Give stress ulcer prophylaxis (a PPI) to patients with bleeding risk factors, such as mechanical ventilation, coagulopathy (platelets $< 50,000/\mu\text{L}$ or INR $> 1.5$), shock, or prior GI bleeding (the 2026 Surviving Sepsis Campaign suggests this for septic patients with risk factors), and stop it when those risk factors resolve. Low-risk patients do not need it.
6. Oral Hygiene Protocols & Chlorhexidine Controversies:
   • Clinical Evolution: While regular mechanical oral hygiene and tooth brushing are universally recommended to clear oral biofilms, routine application of chlorhexidine gluconate (CHG) oral rinses in non-cardiac surgery ICU patients has become controversial. Large meta-analyses identified a potential association between routine CHG oral decontamination and increased all-cause mortality, potentially mediated by subclinical microaspiration of chlorhexidine inducing chemical pneumonitis and acute lung injury. Current guidelines recommend mechanical brushing with sterile water or targeted antiseptic rinses, restricting CHG primarily to cardiac surgery populations.